Biotech Startups

Nu-Tek BioSciences manufactures plant- and yeast-based cell culture nutrients and fermentation supplements for pharmaceutical and biotechnology companies. The company supplies ingredients for mammalian cell culture, industrial fermentation, and clinical nutrition applications.

1 investor

NucleoTech engineers BrainPortal carrier proteins that attach to therapeutic antibodies and oligonucleotides and transport them across the blood-brain barrier non-invasively, using a direct in vivo screening platform to test many candidates simultaneously. It advances internal CNS therapeutics and licenses its carriers to pharma and biotech partners.

1 investor

Nucleus RadioPharma develops and manufactures radiopharmaceutical products, with production facilities capable of scaling to hundreds of thousands of doses per year. It operates sites including a Minnesota location and Springhouse Innovation Park in Pennsylvania.

1 investor

1 investor

NULASTIN is a beauty brand specializing in clinically formulated hair, lash, brow, and skin care products that use elastin replenishing technology. The company serves consumers seeking treatment solutions for hair loss and aesthetic concerns.

1 investor

Nula Therapeutics develops targeted small-molecule medicines that correct how the nuclear envelope regulates gene expression and cellular function. The company focuses on treating age-related diseases including metabolic dysfunction, neurodegeneration, and cancer, and on extending healthspan.

1 investor

Nulixir appears to be a beverage or wellness product company that formulates drinks with herbal extracts, amino acids, and vitamins. The page shows a board of advisors section featuring Gerry, an experienced executive with extensive background in consumer products, manufacturing, and beverage industry turnarounds.

1 investor

Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety. It maintains its own drug pipeline targeting clinically validated pathways and works with pharma and biotech partners on discovery and development.

1 investor

Numenos builds patient-centric biological world models that learn from individual patient data across all diseases to discover the causal mechanisms underlying human biology. The platform applies machine learning to biology with the aim of enabling individualized treatments.

1 investor

Developing 'Epi-drugs' that modulate epigenetic targets for cancer and other diseases.

1 investor

NuPulseCV develops the Voyage device, a cardiac support technology aimed at patients with heart failure who are treated at both major institutions and community hospitals. The company is guided by a scientific advisory board of clinically active cardiologists and cardiac surgeons.

1 investor

Nurami Medical develops surgical sealants and grafts using electrospun nanofiber scaffolds made from resorbable polymers to support tissue engineering and regeneration. The company creates customized biomimetic scaffolds that mimic natural tissue structure for surgical and wound healing applications.

1 investor

Nurotron develops implantable neurostimulation and neuromodulation medical devices for treating sensory and neurological disorders, including cochlear implants for hearing restoration, retinal implants for vision restoration, sacral neuromodulation for bladder dysfunction, and deep brain stimulation for movement disorders.

1 investor

ADM is expanding its natural food colour production capabilities at its Kentucky facility to serve food and beverage manufacturers transitioning away from synthetic colorants due to regulatory pressure and consumer preference shifts. The expansion will increase capacity for liquid and dry-blended color solutions derived from natural sources.

1 investor

NutriLeads employs in-house experts with backgrounds in food technology, microbiology, nutrition, and health across academic and industry sectors. The company appears to operate in the food and nutrition space with a focus on ingredient or food technology solutions.

1 investor

Nutt Bio is developing a single-injection sterilant for male pigs that achieves the same outcomes as surgical castration, used to prevent boar taint. The product is aimed at the swine industry, developed in collaboration with farm vets, researchers, and farm workers.

1 investor

Nuvectis is a biopharmaceutical company developing oral small molecule therapies for cancer, including NXP900, an SRC Family Kinase inhibitor, and NXP800, a GCN2 activator being evaluated in solid tumors such as ovarian cancer and cholangiocarcinoma. Its drug candidates are in early-stage clinical trials for patients with advanced solid tumors.

1 investor

NuVision develops ocular biotherapies rooted in translational research from the University of Nottingham, aiming to provide patients with immediate access to innovative eye surface repair and regeneration treatments. The company operates across the UK, Middle East, Nordics, and central Europe.

1 investor

NuvOx Pharma is a clinical-stage pharmaceutical company developing NanO₂, an oxygen therapeutic drug intended to improve oxygen delivery from lungs to blood and to tissue in order to reverse tissue hypoxia. Its clinical programs target indications including glioblastoma (as a radiosensitizer), stroke, and respiratory distress.

1 investor

1 investor

CyteType is a cell type annotation tool for single-cell RNA-seq data that provides evidence trails for annotations, Cell Ontology standardization, and disease context handling. It supports multiple deployment options including on-premise and cloud hosting, with deterministic reproducibility for regulatory and QC applications.

1 investor

Nykode Therapeutics is a biotechnology company; this investor relations page provides shareholder information, financial reports, and corporate governance details but does not describe the company's specific products or therapeutic focus.

1 investor

LUX BIO develops bioluminescent alternatives to replace chemiluminescent products, targeting the elimination of single-use plastic glow sticks and toxic chemicals from consumer and industrial applications. The company applies biotech solutions to address environmental sustainability challenges.

1 investor

NyquistAI provides an AI-powered intelligence platform that aggregates clinical and regulatory documentation into searchable information and insights for life science companies. It operates in the health technology and life sciences data space.

1 investor